Nuformix, the fibrosis and oncology drug repurposing company, have released positive results from their NXP002 study and outlined the next steps in the development of the treament.
NXP002 is being developed as an inhaled treatment for Idiopathic Pulmonary Fibrosis. The most recent study utilising a human IPF lung tissue model found NXP002 to be non-toxic while producing a strong anti-fibrotic effect.
With the possibility NXP002 targets different disease pathways to existing standards of care, the findings of the study also suggests NXP002 could be used in addition to existing treatments to enhance an anti-fibrotic effect.
Nuformix’s next steps include additional studies on donor lung tissue and the further evaluation of current results to identify disease pathways.
“All parties are delighted with the results from this study, which are as good as we could have hoped for and are the first results from what is the most advanced iteration of this ‘close to patient’ IPF disease model to date,” said Dr Dan Gooding, Executive Director of Nuformix.
“The reduced variability in the resulting data allows us to have high confidence in both NXP002’s anti-fibrotic activity alone, but also in the added anti-fibrotic performance it can deliver on top of existing standards of care. Additivity to standard of care is the most important aspect because it’s the simplest option to investigate in a clinical study and is therefore fast becoming a top priority for potential licensing partners.”
“Having seen the quality of these results, our aim now is to generate datasets from three donors in both human IPF and healthy lung duration of action studies. These data can be generated quickly and will be essential in opening up new discussions with potential licensing partners and support overall progression of the NXP002 programme.”